Evidence map›Paper›PMID 42380824›Full record

SynthesisBMC cancer2026

Immune-related adverse events with cancer clinical benefits: a systematic review and meta-analysis.

Zhijun Li, Qing Sun, Xueling Yang, Jing Ni, Yao Zhang, Jing Wang, Keyu Ding, Guanlin Wang, Huiran Yang, Qiong Yu and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhijun Li *Department of Epidemiology, School of Public Health, Beihua University, Jilin, Jilin Province, 132013, China.
Qing Sun *Department of Clinical Nutrition, Affiliated Hospital of Jilin Medical College, Jilin, Jilin Province, 132013, China.
Xueling YangDepartment of Interventional therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, 300202, Tianjin, China.
Jing NiDepartment of Epidemiology, School of Public Health, Beihua University, Jilin, Jilin Province, 132013, China.
Yao ZhangDepartment of Epidemiology, School of Public Health, Beihua University, Jilin, Jilin Province, 132013, China.
Jing WangDepartment of Epidemiology, School of Public Health, Beihua University, Jilin, Jilin Province, 132013, China.
Keyu DingDepartment of Epidemiology, School of Public Health, Beihua University, Jilin, Jilin Province, 132013, China.
Guanlin WangDepartment of Epidemiology, School of Public Health, Beihua University, Jilin, Jilin Province, 132013, China.
Huiran YangDepartment of Epidemiology, School of Public Health, Beihua University, Jilin, Jilin Province, 132013, China.
Qiong YuDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin Province, 132013, China.
Yan LiDepartment of Epidemiology, School of Public Health, Beihua University, Jilin, Jilin Province, 132013, China. ylzq@beihua.edu.cn.

Funding

BeiHua University Student Innovation Project 202310201295 and 202210201253Health science and Technology capacity Improvement project of Jilin Province 2024A076Jilin Province Science and Technology Development Program YDZJ202301ZYTS128Jilin Province Science and Technology Development Program YDZJ202301ZYTS444Jilin Provincial University Students Innovation project S202410201081National University Student Innovation Program of Beihua University 202310201001Science and Technology Research Program of Education Department of Jilin Province JJKH20230085KJ
6 · The paper itself

Abstract

backgroundGrowing research have reported an association of the occurrence of immune-related adverse events (irAEs) and clinical benefits in patients with immune checkpoint inhibitors (ICIs) treatments, but the findings remain controversial. The aim of this study is to identify whether the incidence of irAEs and their subtypes undergoing ICIs treatment is associated with enhanced efficacy and survival benefits in all solid tumors.

methodsCochrane Library, Embase, PubMed and Web of Science databases were searched from database inception and December 31, 2023. Two reviewers independently extracted data and reviewed the quality items using the Newcastle-Ottawa Scale criteria, and resolved any discrepancies by consensus discussion with third reviewer. We performed the systematic review and meta-analysis in compliance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis and Meta-analysis of Observational Studies in Epidemiology. The main outcomes were irAEs incidence, objective response rate (ORR), overall survival (OS) and progression-free survival (PFS). Subgroup and sensitivity analyses were performed.

resultsA total of 184 articles involving a total of 63,780 patients met the inclusion criteria. The pooled incidence of irAEs in this meta-analysis was 37.3% (95%CI: 34.4%-40.3%). The occurrence of irAEs was associated with increased ORR (RR, 2.32 [95%CI, 2.02-2.67]; I

conclusionsThe intimate association was observed between the development of irAEs and increased response rate and improved survival benefits in patients who treated with ICIs, and may have useful prognostic value in ICIs therapy.

Indexed as

Drug-Related Side Effects and Adverse ReactionsImmune Checkpoint InhibitorsNeoplasmsHumansIncidenceImmune Checkpoint InhibitorsBenefitsCancerEfficacyImmune checkpoint inhibitorsImmune-related adverse events

Identifiers

PMID42380824
PMCPMC13584344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.